JP7111722B2 - 抗がん剤およびその調製方法 - Google Patents

抗がん剤およびその調製方法 Download PDF

Info

Publication number
JP7111722B2
JP7111722B2 JP2019537750A JP2019537750A JP7111722B2 JP 7111722 B2 JP7111722 B2 JP 7111722B2 JP 2019537750 A JP2019537750 A JP 2019537750A JP 2019537750 A JP2019537750 A JP 2019537750A JP 7111722 B2 JP7111722 B2 JP 7111722B2
Authority
JP
Japan
Prior art keywords
group
alkyl
mmol
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529563A (ja
JP2019529563A5 (enExample
Inventor
アラン ケー． ゴーシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2019529563A publication Critical patent/JP2019529563A/ja
Publication of JP2019529563A5 publication Critical patent/JP2019529563A5/ja
Application granted granted Critical
Publication of JP7111722B2 publication Critical patent/JP7111722B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019537750A 2016-09-23 2017-09-22 抗がん剤およびその調製方法 Active JP7111722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398783P 2016-09-23 2016-09-23
US62/398,783 2016-09-23
PCT/US2017/052967 WO2018057897A1 (en) 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof

Publications (3)

Publication Number Publication Date
JP2019529563A JP2019529563A (ja) 2019-10-17
JP2019529563A5 JP2019529563A5 (enExample) 2020-11-05
JP7111722B2 true JP7111722B2 (ja) 2022-08-02

Family

ID=61690726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019537750A Active JP7111722B2 (ja) 2016-09-23 2017-09-22 抗がん剤およびその調製方法

Country Status (14)

Country Link
US (2) US10858371B2 (enExample)
EP (1) EP3515492B1 (enExample)
JP (1) JP7111722B2 (enExample)
KR (1) KR102646702B1 (enExample)
CN (1) CN109862916A (enExample)
AU (1) AU2017331260B2 (enExample)
BR (1) BR112019005885A2 (enExample)
CA (1) CA3037883A1 (enExample)
DK (1) DK3515492T3 (enExample)
IL (1) IL265521B2 (enExample)
MA (1) MA46291A (enExample)
MX (1) MX394670B (enExample)
RU (1) RU2019111768A (enExample)
WO (1) WO2018057897A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862916A (zh) 2016-09-23 2019-06-07 普渡研究基金会 抗癌剂及其制备

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096879A1 (en) 2006-09-08 2008-04-24 University Of Pittsburgh-- Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
WO2009031999A1 (en) 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
US20110178098A1 (en) 2008-06-21 2011-07-21 Webb Thomas R Anticancer compounds and methods of making and using same
WO2014158242A1 (en) 2013-03-13 2014-10-02 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
WO2015077370A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Anti-cancer agents and preparation thereof
US20150307512A1 (en) 2012-12-21 2015-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
JP2015535004A (ja) 2012-11-05 2015-12-07 ファイザー・インク スプライソスタチン類似体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
KR20160125535A (ko) 2008-03-18 2016-10-31 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
US20150025017A1 (en) 2012-02-28 2015-01-22 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
CA2955059A1 (en) 2013-07-15 2015-01-22 Bettina PRONETH Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
KR102092569B1 (ko) * 2013-09-17 2020-03-25 엘지디스플레이 주식회사 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법
AU2017277786A1 (en) * 2016-06-08 2019-01-03 William Marsh Rice University Derivatives of Thailanstatin A, methods of treatment and methods of synthesis thereof
CN109862916A (zh) 2016-09-23 2019-06-07 普渡研究基金会 抗癌剂及其制备

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096879A1 (en) 2006-09-08 2008-04-24 University Of Pittsburgh-- Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
WO2009031999A1 (en) 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
US20110178098A1 (en) 2008-06-21 2011-07-21 Webb Thomas R Anticancer compounds and methods of making and using same
JP2015535004A (ja) 2012-11-05 2015-12-07 ファイザー・インク スプライソスタチン類似体
US20150307512A1 (en) 2012-12-21 2015-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
WO2014158242A1 (en) 2013-03-13 2014-10-02 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
WO2015077370A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Anti-cancer agents and preparation thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chemistry - A European Journal，2011年，17(3)，P.895-904
Heterocycles，2004年，64，P.51-56
Journal of Natural Products，2014年，77(8)，P.1864-1870
Organic Letters，16(23)，2014年，P.6200-6203
Tetrahedron，2006年，62(7)，P.1378-1389

Also Published As

Publication number Publication date
CA3037883A1 (en) 2018-03-29
CN109862916A (zh) 2019-06-07
IL265521B2 (en) 2024-09-01
MX394670B (es) 2025-03-11
JP2019529563A (ja) 2019-10-17
EP3515492A4 (en) 2020-04-08
KR20190077340A (ko) 2019-07-03
BR112019005885A2 (pt) 2020-06-02
RU2019111768A3 (enExample) 2020-11-24
WO2018057897A1 (en) 2018-03-29
IL265521A (en) 2019-05-30
US11851441B2 (en) 2023-12-26
AU2017331260B2 (en) 2024-11-07
IL265521B1 (en) 2024-05-01
MA46291A (fr) 2019-07-31
RU2019111768A (ru) 2020-10-23
AU2017331260A1 (en) 2019-05-16
US20210395265A1 (en) 2021-12-23
DK3515492T3 (da) 2023-08-28
EP3515492A1 (en) 2019-07-31
MX2019003368A (es) 2019-09-16
US20190218228A1 (en) 2019-07-18
EP3515492B1 (en) 2023-07-26
KR102646702B1 (ko) 2024-03-11
US10858371B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
JP6873221B2 (ja) ベンズアミド及びニコチンアミド化合物及びこれを使用する方法
UA75716C2 (en) Thiopene- and thiazolesulfonamides as antineoplastic agents, pharmaceutical composition based thereon
JP6929903B2 (ja) 抗癌剤およびその調製方法
JP6622290B2 (ja) Ｈｉｖ−１プロテアーゼ阻害剤およびその用途
JP2024164181A (ja) カリスポンジオリド、その類似体、およびそれらの使用
KR100915287B1 (ko) 티아디아졸린 유도체
JP7111722B2 (ja) 抗がん剤およびその調製方法
CN101565409A (zh) 哌嗪或高哌嗪草酰肼类化合物及其制备方法和用途
JP7098643B2 (ja) Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤
CN103214486B (zh) β-咔啉衍生物或可药用盐，其制备方法及其抗肿瘤的应用
HK40006497A (en) Anti-cancer agents and preparation thereof
HK40062614A (en) Anti-cancer agents and preparation thereof
CN105541696A (zh) 一种抗肿瘤的化合物及其制备方法和应用
WO2024027695A1 (zh) 作为her2抑制剂的化合物
JP2001524067A (ja) 放射線感作性タキサン類およびその医薬製剤

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200915

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220721

R150 Certificate of patent or registration of utility model

Ref document number: 7111722

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250